Loading…
← CockpitCompetitor Analysis › 688315.SS Novogene Co., Ltd. Class AOpen in the cockpit ↗

Novogene Co., Ltd. Class A688315.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical/Nursing Services

Global genomics services company running DNA sequencing for research customers, with major US and UK labs.

≈ A global genomics-sequencing service, akin to a research-focused Illumina customer/partnerMomentum leader 92
Mkt cap
$1.01B
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$59.7M
20-day average traded
Fwd P/E
44.8×
forward earnings
ROIC−WACC
+8.6 pp
WACC 9.6%
Hurdle
+6 pp
Req g minus delivered
Next earnings
142 days
9 Apr 2027
Close · CNYCN¥16.96
1D-2.3%
1W-16.5%
1M-7.0%
3M+2.8%
6M+12.7%
YTD+27.7%
1Y+14.6%
ATR %10.4%
52w lowhigh27.6% off high

What Novogene does

Global genomics services company running DNA sequencing for research customers, with major US and UK labs.

Charges per sample for sequencing and analysis, running the samples on instruments bought from sequencer makers, so revenue follows research funding and sample volumes, and the price per sample has fallen over time as the technology improved. Labs outside China, including in the US and UK, serve overseas customers.

In one line: A global genomics-sequencing service, akin to a research-focused Illumina customer/partner.

Products and services

  • Next-gen sequencing services
  • Bioinformatics analysis
  • Genomics research consumables

Customers

  • Academic/research institutions
  • Biotech/pharma R&D

Where it sits in the supply chain

  • Health Care
  • Life-science services
  • DNA sequencing / genomics services

What could go right

  • Global genomics/precision-medicine research demand

What could go wrong

  • Sequencing-price competition
  • Geopolitical scrutiny of Chinese genomics data

Moat: narrow (scale, installed base). Large global sequencing capacity and turnaround-time reputation built over a decade.

Headquarters: Beijing, China · Founded: 2011 · Employees: 2,225

Named competitors

Novogene at a glance

Size Novogene (688315.SS) is a China Health Care company (Medical/Nursing Services) with a market value of $1.01B, the 2144th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.96 on 18 Nov 2026.

Performance Over six months the shares gained 12.7%, against +0.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 5.8% over the last twelve months (peer median +6.8%); the operating margin is 6.6% (peer median 9.2%).

Valuation It trades at 44.8× forward earnings against a peer median of 21.4× (2nd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 8.6 points above its cost of capital (9.6% WACC).

Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026688315.SS 114Peer median 105
Six months, rebased to 100: Novogene against the median of its 20 peers (local-currency closes).

Novogene financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.30BCN¥2.21BCN¥2.11BCN¥2.00BCN¥1.92B
Revenue growth—+5%+5%+4%—
Gross profitCN¥1.08BCN¥914MCN¥901MCN¥830MCN¥820M
EBITDAn/aCN¥292MCN¥359MCN¥328MCN¥336M
Net incomeCN¥150MCN¥167MCN¥197MCN¥178MCN¥177M
Free cash flowCN¥238MCN¥145MCN¥242MCN¥241MCN¥97.1M
Capital expenditureCN¥144MCN¥104MCN¥183MCN¥117MCN¥217M
Total debtCN¥65.0MCN¥71.6MCN¥42.8MCN¥42.2MCN¥49.3M

Quarterly statements and history in the cockpit →

Novogene competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%AHCOREG4694GDRXTHYROCARENUTXTTALOMETROPOLISOPKPNTGDIA1959401951LMRI1833USPH4544NEPHROPLUS688315.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Novogene is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×REG4694GDRXTHYROCARENUTXTTALOMETROPOLISPNTGDIA195940CLARI1951LMRI1833GMRSUSPH4544NEPHROPLUS688315.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Novogene is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%AHCOREG4694GDRXTHYROCARENUTXGMRS688315.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Novogene is the large dot.

Novogene competitors and peer comparison

Head to head with its named competitors (688315.SS vs 300676.SZ vs ILMN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Novogene 688315.SS$1.01B+13%+6%7%44.8×13.9%
BGI Genomics 300676.SZ$2.13B-15%0%-14%126.7×n/a
Illumina ILMN$31.8B+48%+6%21%35.2×27.2%

How Novogene compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Novogene against its 20 peers (data as of 18 Nov 2026)
Measure688315.SSPeer medianRank in peer set
1-month return-7.0%+2.4%4th lowest of 21
6-month return+12.7%+0.9%7th highest of 21
Distance from 52-week high-27.6%-23.8%8th lowest of 21
Revenue growth (TTM)+5.8%+6.8%10th lowest of 21
Operating margin6.6%9.2%9th lowest of 21
Forward P/E44.8×21.4×2nd most expensive of 19
Growth the price implies (Req g, 7 yrs)13.9%8.5%8th most demanding of 19
Growth delivered (Del g)+8.2%+11.5%8th lowest of 19
Hurdle (Req g minus delivered)+5.7 pp-0.4 pp6th most demanding of 19
ROIC minus cost of capital+8.6 pp-1.7 pp3rd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%

Questions

Who are Novogene's main competitors?
Named competitors: BGI Genomics (300676.SZ), Illumina (as supplier/competitor) (ILMN). The cockpit's measured peer set (industry) also includes AdaptHealth (AHCO), Regis Healthcare (REG.AX), BML (4694.T), GoodRx (GDRX), Thyrocare Technologies (THYROCARE.NS), Nutex Health (NUTX).
Is Novogene expensive compared with its peers?
On forward p/e it trades at 44.8× against a peer median of 21.4×, 2nd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Novogene stock performed?
Over six months to 18 Nov 2026 the shares returned +12.7% against +0.9% for the median peer; over one year +14.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.